Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections

Karl Weiss, Robin L Allgren, Sarah Sellers, Karl Weiss, Robin L Allgren, Sarah Sellers

Abstract

Fidaxomicin is a novel macrocyclic antibiotic recently approved by the US Food and Drug Administration for the treatment of Clostridium difficile-associated diarrhea in adults. We reviewed safety data from nonclinical studies and clinical trials (phases 1, 2A, and 3) with fidaxomicin. In nonclinical studies, fidaxomicin was administered orally at approximately 1 g/kg/d to dogs for up to 3 months with no significant target-organ toxicities observed. A total of 728 adults have received oral fidaxomicin in clinical trials to date: 116 healthy volunteers and 612 patients with C. difficile infection. In phase 3 clinical trials, fidaxomicin was well tolerated, with a safety profile comparable with oral vancomycin. There were no differences in the incidence of death or serious adverse events between the 2 drugs. Fidaxomicin appears to be well tolerated. Continued monitoring of adverse events in the postmarketing setting will provide additional information about the full safety profile of fidaxomicin.

References

    1. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298:531–4.
    1. Tedesco FL, Barton RW, Alpers DH. Clindamycin-associated colitis: a prospective study. Ann Intern Med. 1974;81:429–33.
    1. McDonald LC, Owings M, Jernigan DB. Clostridium difficile in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis. 2006;12:409–15.
    1. Kyne L, Hamel MB, Polavaram L, Kelly CP. Health-care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346–53.
    1. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–9.
    1. Zilberberg MA, Shorr AF, Kollef M. Increase in adult Clostridium difficile–related hospitalizations and case-fatality rate, United States 2000–2005. Emerg Infect Dis. 2008;14:929–31.
    1. Browne RA, Fekety R, Jr, Silva J, Boyd DI, Work CO, Abrams GD. The protective effect of vancomycin on clindamycin-induced colitis in hamsters. Johns Hopkins Med J. 1977;141:183–92.
    1. Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis. 2008;46:1489–92.
    1. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis. 1997;25(Suppl 2):S206–10.
    1. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile–associated diarrhea stratified by disease severity. Clin Infect Dis. 2007;45:302–7.
    1. Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile–associated diarrhea. Clin Infect Dis. 1996;22:813–8.
    1. Louie TJ, Miller MA, Mullane KM, et al. OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–31.
    1. Anti-Infective Drugs Advisory Committee. Dificid™ (fidaxomicin tablets) for the treatment of Clostridium difficile infection (CDI), also known as Clostridium difficile–associated diarrhea (CDAD), and for reducing the risk of recurrence when used for treatment of initial CDI. . Accessed 11 November 2011.
    1. Shue YK, Sears PS, Shange S, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother. 2008;52:1391–5.
    1. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJC. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2009;53:223–8.
    1. Gorbach S, Weiss K, Sears P, Pullman J. Safety of fidaxomicin versus vancomycin in treatment of Clostridium difficile infection [poster L1-1640] In: Program and abstracts of the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: ICAAC, 2009.
    1. Aradhyula S, Manian FA, Hafidh SA, Bhutto SS, Alpert MA. Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function. South Med J. 2006;99:518–20.
    1. Osawa R, Kaka AS. Maculopapular rash induced by oral vancomycin. Clin Infect Dis. 2008;47:860–61.
    1. Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology. 1985;88:681–4.
    1. McGrath NM, Kent-Smith B, Sharp DM. Reversible optic neuropathy due to metronidazole. Clin Experiment Ophthalmol. 2007;35:585–6.
    1. Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S19–31.
    1. Weiss K, Boisvert A, Chagnon M, et al. Multipronged intervention strategy to control an outbreak of Clostridium difficile infection (CDI) and its impact on the rates of CDI from 2002 to 2007. Infect Control Hosp Epidemiol. 2009;30:156–62.
    1. ViroPharma Inc. Vancocin HCl capsules (vancomycin hydrochloride capsules, USP) [prescribing information] . Accessed 14 November 2011.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren